$0.18
+0.00 (+0.34%)
Open$0.18
Previous Close$0.18
Day High$0.18
Day Low$0.18
52W High$5.14
52W Low$0.17
Volume—
Avg Volume840.8K
Market Cap7.77M
P/E Ratio—
EPS$-1.68
SectorBiotechnology
Analyst Ratings
Sell
8 analysts
Price Target
+27,475.3% upside
Current
$0.18
$0.18
Target
$49.47
$49.47
$36.23
$49.47 avg
$53.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.58M | 848.4K | 9.03M |
| Net Income | -86,807,396 | -80,993,442 | 1.99M |
| Profit Margin | -5,491.3% | -10,050.9% | 22.0% |
| EBITDA | -89,596,160 | -92,813,868 | 3.04M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | — | -24.1% | +1.4% |
| Debt/Equity | 0.00 | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |